Human procalcitonin and the preparation and use thereof

Details Human procalcitonin and the preparation and use thereof Human procalcitonin and the preparation and use thereof

2005-06-14

2005-06-14

Mosher, Mary E. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S192100, C514S012200, C435S007100, C436S501000, C530S356000

Reexamination Certificate

active

06905687

ABSTRACT:
The invention relates to human procalcitonin and the preparation and use thereof. In particular, a process for preparing human procalcitonin is described wherein a gene coding for a polypeptide comprising the amino acid sequence of human procalcitonin is inserted into a vector; a host organism is transformed with this gene-containing vector; and the polypeptide expressed by the host organism is isolated. Furthermore the use of the polypeptides according to the invention, in particular as medicaments and diagnostic agents is described.

REFERENCES:
patent: 3057782 (1962-10-01), Lindner et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 5340716 (1994-08-01), Ullman et al.
patent: 5545834 (1996-08-01), Singh et al.
patent: 5740800 (1998-04-01), Hendrickson et al.
patent: 5915240 (1999-06-01), Karpf
patent: 5993811 (1999-11-01), Becker et al.
patent: 1155134 (1958-06-01), None
patent: 198 47 690 (2000-04-01), None
patent: 199 03 336 (2000-08-01), None
patent: 0 080 614 (1982-11-01), None
patent: 0 227 054 (1986-12-01), None
patent: 0 246 446 (1987-04-01), None
patent: 0 411 945 (1990-08-01), None
patent: 0 515 194 (1992-05-01), None
patent: 0 656 121 (1993-08-01), None
patent: 0 997 735 (1999-09-01), None
patent: 1 026 506 (2000-01-01), None
patent: 1 111 050 (2001-06-01), None
patent: WO 98/33524 (1988-01-01), None
patent: WO 95/06877 (1995-03-01), None
patent: WO 95/25172 (1995-09-01), None
Rehli et al (BBRC 226: 420-425, 1996).
Snider et al (Journal of Investigative Medicine 45:552-560, 1997).
Le Moullec et al (FEBS Lett. 167:93-97, 1984).
Dialog (R) File 351: English Abstract of EP 1 026 506 A1.
Dialog (R) File 351: English Abstract of EP 0 997 735 A2.
S. Wrenger et al., “Amino-terminal Truncation of Procalcitonin, a Marker for Systemic Bacterial Infections, by Dipeptidyl Peptidase IV (DP IV), 2000”Federation of European Biochemical Societies Letters,466, No. 1, (2000), pp. 155-159.
Xiao-Quing Liu et al., “A Novel Method for Increasing Production of Mature Proteins in the Periplasm ofEscherichia coli,”Protein Science(1999), vol. 8, 1999, Cambridge University Press, The Protein Society, pp. 2085-2089.
Rainer Fischer et al., “Molecular Farming of Recombinant Antibodies in Plants,”Biol. Chem.,vol. 380, Jul./Aug. 1999, pp. 825-839.
Eric S. Nylen, et al., “Mortality is increased by Procalcitonin and Decreased by an Antiserum Reactive to Procalcitonin in Experimental Sepsis,”Crit. Care Med.1998, vol. 26, No. 6, pp. 1001-1006.
W. Karzai et al., “Procalcitonin—A New Indicator of the Systemic Response to Severe Infections,” Infection, 6,A Journal of Infectious Disease—Clinical Study and Treatment,vol. 25, 1997, pp. 329-334.
Michael Rehli et al., “Molecular Cloning and Expression of Mouse Procalcitonin,”Biochemical and Biophysical Research Communications226, pp. 420-425 (1996).
Edwin F. Ullman et al., “Luminescent Oxygen Channeling Assay (LOCI™): Sensitive, Broadly Applicable Homogeneous Immunoassay Method,”Clinical Chemistry,vol. 42, No. 9, 1996, pp. 1518-1526.
Keith M. Thompson et al., “The Efficient Production of Stable, Human Monoclonal Antibody-Secreting Hybridomas from EBV-transformed Lymphocytes Using the Mouse Myeloma X63-Ag8.653 as a Fusion Partner,”Journal of Immunological Methods,vol. 94, 1996, pp. 7-12.
Sebastian Messerschmid, “Erzeugung von Polyklonalen Antikörpen in Nicht-Säugern,”BIOforum,Nov. 1996, pp. 500-502.
Edwin F. Ullman et al., “Luminescent Oxygen Channeling Immunoassay: Measurement of Particle Binding Kinetics by Chemiluminescence,”Proc. Natl. Acad. Sci, USA,vol. 91, 1994, pp. 5426-5430.
Gérard Mathis, “Rare Earth Cryptates and Homogeneous Fluoroimmunoassays with Human Sera,”Clin. Chem.,vol. 39, No. 9, 1993, pp. 1953-1959.
Andrew Hiatt et al., “Assembly of Antibodies and Mutagenized Variants in Transgenic Plants and Plant Cell Cultures,”Genetic Engineering,vol. 14, 1992, pp. 49-64.
James W. Larrick et al., “Recombinant Antibodies,”Review,vol. 2, 1991, pp. 172-189.
J. Michael Conlon et al., “Structural Characterization of a High Molecular-mass Form of Calcitonin [procalcitonin-(60-116)-peptide] and Its Corresponding N-terminal Flanking Peptide [procalcitonin-(1-57)-peptide] in a Human Medullary Thyroid Carcinorma,”Biochem.,vol. 256, 1988, pp. 245-250.
Pascale P. Ghillani et al., “Identification and Measurement of Calcitonin Precursors in Serum of Patients with Malignant Diseases,”Cancer Research,vol. 49, 1989, pp. 6845.
Pascale Ghillani et al., “Monoclonal Antipeptide Antipeptide Antibodies As Tools To Dissect Closely Related Gene Products,”The Journal of Immunology,vol. 141, 1988, pp. 3156-3163.
M. Philip Bailey et al., “On the Use of Fluorescent Labels in Immunoassay,”Journal of Pharmaceutical&Biomedical Analysis,vol. 5, 1987, pp. 649-658.
Kazuaki Kitano et al., “Production of Human Monoclonal Antibodies by Heterohybridomas,”Appl Microbiol Biotechnol,vol. 24, 1986, pp. 282-286.
Sidney Udenfriend et al., “Scintillation Proximity Radioimmunoassay Utilizing125l-labeled Ligands,”Proc. Natl. Acad. Sci, USA,vol. 82, 1985, pp. 8672-8676.
Moullec et al., “The Complete Sequence of Human Preprocalcitonin,”Federation of European Biochemical Societies,vol. 167, 1984, pp. 93-97.
R.C. Boguslaski et al., “Homogeneous Immunoassays,”Applied Biochemistry and Biotechnology,vol. 7, 1982, pp. 401-414.

Affiliated with

Also associated with

Rating

Human procalcitonin and the preparation and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human procalcitonin and the preparation and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human procalcitonin and the preparation and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3518431